| Followers | 65 |
| Posts | 10174 |
| Boards Moderated | 0 |
| Alias Born | 03/29/2015 |
Wednesday, October 08, 2025 10:01:12 AM
Will there ever be a milestone that doesn’t take two years to reach? Labeling alone typically takes two months. But with NWBO, of course, it’s a minimum of six months to a year — because it’s “complex,” blah blah blah. Is it really that complex, or is management just incapable of handling tasks in a timely manner?
The biggest hope created by FINALLY getting the application submitted into the hands of the MHRA was that NWBO would no longer be able to create delays and that MHRA would give us an up or down decision and one way or another we would know if the last decade plus had been wasted.
I stated as much multiple times here and not one person, especially on the Pump Crew said ‘Errrr Happy, just so you and everybody knows, the application is going to be more of an extended dialogue than something the regulator reviews and NWBO can drag things out an extra 60 days each time MHRA asks a question. Oh and Happy, there’s no limit to the number of questions MHRA can ask (except that imposed by their consciences when they think of how many GBM die because of each one).
So either all the folks talking (and wittingly or not, pumping) about eager and quick the MHRA would be ‘because NWBO has a good relationship with them and the UK wants to first be etc. did one of two things:
1. They spoke out of ignorant over optimism and no real knowledge of the process, in which case any positive speculation about time frames or short cuts. by any of those folks should be viewed with even more than the usual skepticism.
Or (and this is worse)
2. They knew in advance about how the MHRA process worked including RFIs but chose not to mention anything about it, for reasons of their own.
I think #1 is more likely overall.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
